Skip to content

Pharmacogenetics (PGx) in Pain Management | Pain Pod

Pharmacy Podcast Network

26m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode of the Pain Pod explores pharmacogenetics and pharmacogenomics in pain management, focusing on how single gene variations impact patient responses to medications. The host explains basic genetic terminology, enzyme metabolizer phenotypes, and the role of hepatic cytochrome P450 enzymes like 2D6, 3A4, and 2C19 in processing drugs. The discussion details clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium, known as CPIC, and examines how genetic profiles guide medication adjustments for opioids, NSAIDs, SNRIs, and tricyclic antidepressants. Listeners receive a thorough breakdown of metabolic phases, population-specific metabolizer variations, and practical avenues for implementing PGX testing in clinical practice.

  • CPIC serves as the gold standard for clinical pharmacogenetics guidelines, offering detailed online resources to help healthcare professionals determine recommended actions based on a patient's gene-drug interactions. 10:15
  • Phase one drug metabolism is dominated by hepatic cytochrome P450 enzymes, with CYP450 3A4 and 2D6 acting as the heavy hitters for pain management medications. 13:10
  • When encountering patients with identified CYP450 2C9 concerns, clinicians can consider non-CYP metabolized alternatives such as etodolac, ketoprofen, or nabimetone. 17:38
  • For tricyclic antidepressants, CPIC recommends avoiding utilization in ultra-rapid or poor metabolizers of CYP450 2D6 to prevent either lack of efficacy or dangerous side effect buildup. 21:58

Chapters

  1. 0:05
    Podcast Introduction and Host Overview

    The episode opens with the global pharmacy podcast network intro and introduces Dr. Mark Grofely as the host of Pain Pod.

  2. 1:11
    Key Terminology: Genes, Genotype, and Phenotype

    Basic genetic terms are clarified, setting the foundation for understanding PGx in clinical practice.

  3. 1:44
    Pharmacogenetic Variants and Drug Targets

    Discussion of how gene changes affect drug receptors, enzymes, and transporters, and the importance of metabolizer phenotypes.

  4. 2:44
    Defining Pharmacogenetics and Pharmacogenomics

    The host explains the difference between PGx and PGxomics, emphasizing gene variation impact on drug response.

  5. 5:10
    Integrating PGx into Clinical Practice and Workflow

    Practical steps for ordering tests, interpreting reports, and coordinating with pharmacists and clinics.

  6. 6:00
    Future Directions and Patient Engagement

    Discussion of patient-driven PGx testing, cost considerations, and the role of CPESN and other resources.

  7. 9:34
    Clinical Guidelines for PGx Actionable Recommendations

    Overview of CPIC, DPWG, and FDA guidelines that translate PGx results into prescribing actions.

  8. 15:10
    Applying PGx to Opioid Therapy

    The host reviews how CYP2D6 metabolizer status influences codeine and tramadol prescribing.

  9. 16:46
    PGx Impact on NSAIDs and Adjuvant Medications

    Exploration of CYP2C9, CYP2D6, and CYP3A4 roles in NSAIDs, SNRIs, and TCAs, with CPIC recommendations.

  10. 26:03
    Episode Wrap‑Up and Listener Takeaways

    The host summarizes key points, encourages feedback, and promotes the previous codeine episode.

Highlights

  • 1:56

    Defining Pharmacogenetics Versus Pharmacogenomicsinsight

    The host defines pharmacogenetics as the study of how single gene variations impact responses to one specific medication, while pharmacogenomics examines how a patient's entire genome influences overall drug response.

  • 6:07

    Understanding Enzyme Metabolizer Phenotypesinsight

    Enzyme metabolizers are categorized into phenotypes ranging from poor and intermediate to normal, extensive, and ultra-rapid, with the bookends representing extreme metabolic rates.

  • 7:50

    Automatic Translation in PGX Reportsinsight

    Pharmacogenetic reports function like automated translation tools, often utilizing color-coded systems such as red for stopping a medication and green to indicate safety.

  • 9:34

    The Three Main PGX Guidelinesstrategy

    The host outlines three major clinical guideline sources: the Dutch Pharmacogenetics Working Group, the FDA table of pharmacogenomic biomarkers, and the CPIC gold standard.

  • 14:46

    Codeine and Tramadol Activation Risksinsight

    Both codeine and tramadol rely on CYP450 2D6 for activation or conversion to morphine, meaning ultra-rapid metabolizers risk over-activation and subsequent severe side effects.

  • 15:57

    Population Frequencies of 2D6 Variantsdata

    Data from population studies indicate that approximately nine to twenty-one percent of individuals of Asian ethnicity are ultra-rapid metabolizers of CYP450 2D6.

  • 16:55

    NSAID Metabolism Through 2C9data

    Over half of all nonsteroidal anti-inflammatory drugs are metabolized by CYP450 2C9, and approximately one-third of individuals of white ethnicity are intermediate metabolizers.

  • 19:57

    TCA Methyl Group Modificationsinsight

    Tricyclic antidepressants transition from tertiary to secondary amines through the loss of methyl groups, a metabolic process heavily reliant on CYP450 2C19 and 2D6.

Quotes

  • “Pharmacogenetics, that's, you know, the textbook is a study of how a single gene variation basically impacts the body's response to one specific medication.”
    Unnamed speaker · 2:44
  • “When initiating or even continuing or titrating medications for a given patient over time, PGX profiles can help.”
    Unnamed speaker · 12:15
  • “If somebody's a 2D6 ultra rapid metabolizer, we generally would say, the guidelines would say, CPIC, avoid codeine and avoid tramadol.”
    Unnamed speaker · 16:20
  • “PGX is part of the overall risk reduction strategy for best practices in pain management, but it is one thing along the way.”
    Unnamed speaker · 23:10

About this episode

As a follow-up to our investigative reporting previous Pain Pod episode involving codeine and pharmacogenetics, now we’re going to review the pharmacogenic concerns for pain medications! Come one, come all, to the Pain Pod!!! P. S. Want to contribute or hear about a pain pearl of your own? Message Pain Guy on www.painguy.us to directly reach Mark and have your voice heard! Pain Guy• www.painguy.us PGx Population Percentages• Genetic Factors in Drug Metabolism (2008): http://www.aafp.org/afp/2008/0601/p1553.htmlPGx CPIC (Gold Standard)• https://www.clinpgx.org/cpic?s= Audio Link: https://drive.google.com/file/d/10SruWA8tIpC2ymRKt6rcl-OaHAn3awvM/view

Transcript

0:00
26:57

4,343 words · 3 speakers

Topics

  • 2D6
  • CPIC
  • tramadol
  • 2C9
  • Pain Pod
  • NSAIDs
  • codeine
  • 2C19
  • TCAs
  • CPESN

Page updated · transcript and summary are machine-generated